Compare Boston Scientific Corporation (BSX) vs Equinix Inc (EQIX) Price & Performance

Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.

The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.

Equinix (EQIX) trades at $1,061.19, up 1.71% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing revenue expectations. Strong demand for AI infrastructure and record bookings support a raised long-term growth outlook. However, high valuation ratios, including a P/E of 66.44 and EV/EBITDA of 27.58, reflect premium pricing. Cash flow trends show significant capital expenditures, with net cash flow negative in 2025 and 2026.

The outlook for EQIX is cautiously optimistic, driven by AI-driven demand and strategic partnerships, but elevated debt levels and valuation multiples pose risks. Analyst consensus is strongly bullish with a $1,120 price target, though investors should monitor execution on growth targets and debt management amid competitive and macroeconomic pressures.